By Nell Mackenzie and Samuel Indyk LONDON, Feb 13 (Reuters) - Hedge fund bets against Hims & Hers Health hit their highest in ...

Hims & Hers is rated Hold as regulatory/legal risks hit its GLP-1 weight-loss pivot; resilient core & strong liquidity noted. Click to read more on HIMS stock.

Downgrade Hims & Hers Health, Inc. to Hold as FDA scrutiny and Novo’s lawsuit threaten compounded GLP-1 revenue. Click for ...

What Happened? A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price ...

Today, Feb. 9, 2026, investors are reevaluating Hims & Hers after it pulled its weight-loss pill, facing legal action and FDA ...

Narrated by Common, Hims & Hers' 2026 Super Bowl ad positions affordability as part of the solution to the income disparities shaping health outcomes.

NEW YORK, Feb 5 (Reuters) - Online telehealth company Hims and Hers Health will begin offering copies of Novo Nordisk's new Wegovy pill at an introductory price of $49 per month, the company said ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $40.5, a high estimate of $60.00 ...

It has been about a month since the last earnings report for Hims & Hers Health, Inc. (HIMS). Shares have lost about 15.1% in that time frame, underperforming the S&P 500. Will the recent negative ...

Financial giants have made a conspicuous bullish move on Hims & Hers Health. Our analysis of options history for Hims & Hers Health (NYSE:HIMS) revealed 13 unusual trades. Delving into the details, we ...

Telehealth company Hims & Hers has added Grail’s blood cancer test Galleri to its offerings as the medtech has now sent off ...